SCIENTURE HOLDINGS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
SCIENTURE HOLDINGS, INC. (SCNX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $6.55 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-04-26.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2021-04-26
- SCIENTURE HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $6.55, a 12.67% decline year-over-year.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $7.50.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $2.57, a 14.33% decline from fiscal 2018.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $3.00, a 368.75% increase from fiscal 2017.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $0.64.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-03-31 | $6.55 10-Q · filed 2021-04-26 | |||||
| 2020-09-30 | $4.42 10-Q · filed 2020-10-26 | |||||
| 2020-06-30 | $4.08 10-Q · filed 2020-07-27 | |||||
| 2020-03-31 | $7.50 10-Q · filed 2020-05-04 | |||||
| 2019-12-31 | $2.57 10-K · filed 2020-03-30 | |||||
| 2019-09-30 | $0.43 10-Q · filed 2019-10-28 | |||||
| 2019-06-30 | $0.43 10-Q · filed 2019-07-26 | |||||
| 2019-05-31 | $2.64 10-K · filed 2020-03-30 | |||||
| 2019-04-30 | $2.46 10-K · filed 2021-03-29 | |||||
| 2018-12-31 | $3.00 10-K · filed 2020-03-30 | $0.50 10-K · filed 2019-03-22 | ||||
| 2017-12-31 | $0.64 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |